Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background Only 50% of atrial fibrillation (AF) patients recommended for oral
anticoagulation (OAC) use these medications, and less than half of them adhere to OAC. In …

Introduction and objectives To assess the effectiveness of direct oral anticoagulants vs
vitamin K antagonists in real-life patients with atrial fibrillation. Methods A systematic review …

Background Patients with warfarin have a potential risk of warfarin-related nephropathy,
which could result in the discontinuation of anticoagulation therapy. The question of whether …

Background There are no head-to-head randomized controlled trials comparing different
direct oral anticoagulants (DOACs). Thus, we systematically reviewed and meta-analyzed …

ABSTRACT Introduction: Direct oral anticoagulants (DOACs) may be regarded as some of
the most successful innovations in recent times. These drugs which were specifically …

Introducción y objetivos Determinar la efectividad de los anticoagulantes orales directos
frente a los antagonistas de la vitamina K en pacientes con fibrilación auricular de la …

Introduction The new user cohort design is widely used to assess the effects of a new drug,
such as dabigatran, but inherently excludes some users due to prior use of the comparator …

Background: We aimed to estimate absolute benefit and harm from treatment with
dabigatran in individual patients with atrial fibrillation, and to select the optimal dose for each …